Figure S8 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

Figure S8 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity

<p>Figure S8R</p>

Na minha lista:

Detalhes bibliográficos
Autor principal:	Shiyi Yu (17079079) (author)
Outros Autores:	Ying Wang (17079082) (author), Xue Gong (17079085) (author), Zhehao Fan (17079088) (author), Zheng Wang (17079091) (author), Zhengyan Liang (17079094) (author), Rui Wu (17079097) (author), Binjie Cao (17079100) (author), Ning Wang (17079103) (author), Caili Bi (17079106) (author), Dan Lv (17079109) (author), Haibo Sun (17079112) (author)
Publicado em:	2025
Assuntos:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Cell Cycle Signal transduction pathways Drug Resistance Regulation of gene expression in drug resistance Endocrine-Related Cancers
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados

Figure S1 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Por: Shiyi Yu (17079079)
Publicado em: (2025)

Figure S2 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Por: Shiyi Yu (17079079)
Publicado em: (2025)

Figure S3 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Por: Shiyi Yu (17079079)
Publicado em: (2025)

Figure S4 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Por: Shiyi Yu (17079079)
Publicado em: (2025)

Figure S5 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Por: Shiyi Yu (17079079)
Publicado em: (2025)

Figure S6 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Por: Shiyi Yu (17079079)
Publicado em: (2025)

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Por: Shiyi Yu (17079079)
Publicado em: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Por: Yufang Bao (15386826)
Publicado em: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Por: Yufang Bao (15386826)
Publicado em: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Por: Yufang Bao (15386826)
Publicado em: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Por: Yufang Bao (15386826)
Publicado em: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Por: Yufang Bao (15386826)
Publicado em: (2025)

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Por: Ossia M. Eichhoff (14964145)
Publicado em: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Por: Nicole A. Traphagen (16677391)
Publicado em: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Por: Nicole A. Traphagen (16677391)
Publicado em: (2025)

Supplementary Data S8 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Por: Naoual Menssouri (16617248)
Publicado em: (2025)

Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
Por: Laura E. Stevens (14961009)
Publicado em: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Por: Alex C.H. Liu (14961921)
Publicado em: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Por: Alex C.H. Liu (14961921)
Publicado em: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Por: Alex C.H. Liu (14961921)
Publicado em: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Por: Alex C.H. Liu (14961921)
Publicado em: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Por: Alex C.H. Liu (14961921)
Publicado em: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Por: Alex C.H. Liu (14961921)
Publicado em: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Por: Seung Yeon Oh (15051017)
Publicado em: (2025)

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Por: Marta J. Llorca-Cardenosa (14961612)
Publicado em: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Por: Marta J. Llorca-Cardenosa (14961612)
Publicado em: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Por: Marta J. Llorca-Cardenosa (14961612)
Publicado em: (2025)

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Por: Marta J. Llorca-Cardenosa (14961612)
Publicado em: (2025)

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
Por: Marta J. Llorca-Cardenosa (14961612)
Publicado em: (2025)

Cannot write session to /tmp/vufind_sessions/sess_i5o2ovflm7kfdnq8juq80f6fvk